Similar Efficacy Seen for Isodose, Dose-Escalated MHFRT, CFRT in Prostate Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 1, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 1, 2025 -- For patients with prostate cancer, isodose and dose-escalated moderately hypofractionated radiotherapy (MHFRT) have similar efficacy as conventionally fractionated radiotherapy (CFRT), but bowel toxicity is seen in association with dose-escalated MHFRT, according to a study published online March 17 in The Lancet Oncology.

Amar U. Kishan, M.D., from the University of California, Los Angeles, and colleagues conducted an individual patient data meta-analysis from randomized phase 3 trials of CFRT versus MHFRT for prostate cancer. Seven phase 3 trials were eligible for inclusion; data were obtained for 3,454 patients from three trials comparing CFRT to isodose MHFRT and 2,426 patients from four trials comparing CFRT to dose-escalated MHFRT.

The researchers found no differences in progression-free survival at a median follow-up of 5.4 years for isodose MHFRT and 7.1 years for dose-escalated MHFRT. For isodose and dose-escalated MHFRT, there were no increased odds of grade 2 or higher genitourinary toxic effects. With dose-escalated, but not isodose MHFRT, the odds of grade 2 or higher gastrointestinal toxic effects were significantly greater (odds ratio, 1.48). Odds of urinary quality-of-life decrement or bowel quality-of-life decrement were no different for isodose MHFRT. Greater odds of bowel quality-of-life decrement were seen with dose-escalated MHFRT (odds ratio, 1.68), but no greater urinary quality-of-life decrement was seen.

"This meta-analysis provides the strongest evidence to date suggesting an isodose MHFRT regimen could be the preferred MHFRT regimen for all risk groups," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-02 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords